Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Trading 10-29 14:04:57 EDT

188.45

-0.27

-0.14%

High191.90	Low187.38	Vol544.72K
Open187.38	D1 Closing188.72	Amplitude2.40%
Mkt Cap40.39B	Tradable Cap34.86B	Total Shares214.34M
T/O103.62M	T/O Rate0.29%	Tradable Shares185.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":188.45,"timestamp":1793297097163,"preClose":188.72,"halted":0,"volume":544715,"delay":0,"changeRate":-0.001430690970750372,"floatShares":185000000,"shares":214336418,"eps":-8.921187,"marketStatus":"Trading","change":-0.27,"latestTime":"10-29 14:04:57 EDT","open":187.38,"high":191.8999,"low":187.38,"amount":103618073.1517,"amplitude":0.02395,"askPrice":188.5,"askSize":111,"bidPrice":188.16,"bidSize":41,"shortable":3,"etf":0,"ttmEps":-8.921187,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793304000000},"marketStatusCode":2,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":188.72,"preHourTrading":{"tag":"盘前","latestPrice":189,"preClose":188.72,"latestTime":"09:22 EDT","volume":954,"amount":180010.94688,"timestamp":1793280136420,"change":0.28,"changeRate":0.001484,"amplitude":0.010598},"postHourTrading":{"tag":"盘后","latestPrice":186.18,"preClose":188.72,"latestTime":"19:52 EDT","volume":24213,"amount":4579966.1345,"timestamp":1793231526190,"change":-2.54,"changeRate":-0.013459,"amplitude":0.013459},"volumeRatio":0.557209,"optionData":{"bulkOrders":[{"symbol":"RVMD","call":false,"expireDate":1795150800000,"strike":"150.0","timestamp":1793281564089,"price":1.74,"volume":1500,"amount":261000,"type":"+"},{"symbol":"RVMD","call":false,"expireDate":1795150800000,"strike":"175.0","timestamp":1793281564089,"price":6.09,"volume":1500,"amount":913500,"type":"-"}]},"impliedVol":0.6461,"impliedVolPercentile":0.757},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"1147884219","title":"Earning Preview: Revolution Medicines, Inc. Q3 revenue expected to increase by 15.11%, institutional views are predominantly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1147884219","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1147884219?lang=en_us&edition=fundamental","pubTime":"2026-10-28 16:54","pubTimestamp":1793177699,"startTime":"0","endTime":"0","summary":"Abstract Revolution Medicines, Inc. will release quarterly results on November 04, 2026 Post-Mkt; this preview synthesizes consensus forecasts, the company’s prior-quarter baselines, and recent...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Revolution Medicines, Inc. Q3 revenue expected to increase by 15.11%, institutional views are predominantly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679228502","title":"Should Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2679228502","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679228502?lang=en_us&edition=fundamental","pubTime":"2026-10-29 21:40","pubTimestamp":1793281217,"startTime":"0","endTime":"0","summary":"Revolution Medicines reported new exploratory subgroup data from the Phase 3 RASolute 302 trial and received a positive EMA CHMP opinion for RASONQUE in previously treated metastatic pancreatic cancer, reinforcing the clinical and regulatory profile of its lead RAS targeted therapy.\nThe breadth of overall survival benefit across RAS genotypes and chemotherapy backbones, combined with a potential first EU approval, directly affects how durable and scalable RASONQUE could be within the broader...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/should-pancreatic-cancer-trial-progress-require-action-from","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/should-pancreatic-cancer-trial-progress-require-action-from","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861214812.USD","BK4588","IE0009354923.USD","LU1861219969.SGD","IE0002141913.USD","IE0009355771.USD","BK4097","LU1978683503.SGD","BK4211","CANC","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0124384867.USD","PRGS","LU0348723411.USD","IE00BD6J9T35.USD","IDNA","LU1861215975.USD","LU1861220033.SGD","LU1983260115.SGD","ISBC","IE00BJJMRZ35.SGD","LU0724618433.USD","ONG","LU2360107325.USD","BK4585","IE00BJT1NW94.SGD","LU2298322129.HKD","BK4139","IE00BFMHRM44.USD","IE00BZ199S13.USD","RVMD","BK4141","LU1720051108.HKD","ONX","PTH","LU2357305700.SGD","LU1854103824.USD","BBH","LU0889565916.HKD","LU1854104046.USD","LU1548497426.USD","IE00B2B36J28.USD","BK4605","BK4512","ON","LU0320765992.SGD","LU1720051017.SGD","IE00B4R5TH58.HKD","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679249410","title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Reports Sale of $431,946.90 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2679249410","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679249410?lang=en_us&edition=fundamental","pubTime":"2026-10-29 06:00","pubTimestamp":1793224853,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Reports Sale of $431,946.90 in Common SharesRevolution Medicines Chief Global Commercialization Officer Anthony Mancini sold","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nNDL9ndQcQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Reports Sale of $431,946.90 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0009355771.USD","IE00B4R5TH58.HKD","RVMD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0109394709.USD","BBH","IE0009354923.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","PTH","IDNA","CANC","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678875435","title":"RBC Capital Keeps Their Buy Rating on Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678875435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678875435?lang=en_us&edition=fundamental","pubTime":"2026-10-28 09:56","pubTimestamp":1793152568,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on Revolution Medicines yesterday and set a price target of $260.00. Timashev covers th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-revolution-medicines-rvmd-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-revolution-medicines-rvmd-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678548393","title":"Revolution Medicines Participates in Guggenheim and Jefferies Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2678548393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678548393?lang=en_us&edition=fundamental","pubTime":"2026-10-28 04:15","pubTimestamp":1793132112,"startTime":"0","endTime":"0","summary":"Revolution Medicines Participates in Guggenheim and Jefferies Healthcare ConferencesRevolution Medicines CEO and Chairman Mark A. Goldsmith will participate in two investor conferences in November 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDLc0Hj78:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE0009354923.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE0002141913.USD","IE0009355771.USD","CANC","LU2210150020.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","NDAQ","IDNA","IE00BJJMRZ35.SGD","BCDF","SG9999014039.USD","IE00BQXX3C00.GBP","BK4585","IE00BJT1NW94.SGD","IE00BQXX3D17.EUR","BK4139","IE00BN0W2V16.EUR","RVMD","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","PTH","BBH","LU0889565916.HKD","IE00BN0W2W23.USD","IE00B2B36J28.USD","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","LU0320765992.SGD","SG9999014005.SGD","IE00BQXX3F31.USD","IE00B4R5TH58.HKD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678858404","title":"Revolution Medicines to Participate in November 2026 Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2678858404","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678858404?lang=en_us&edition=fundamental","pubTime":"2026-10-28 04:05","pubTimestamp":1793131500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Oct.  27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering inno","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/27/3389602/0/en/revolution-medicines-to-participate-in-november-2026-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4605","LU0724618433.USD","LU0889565916.HKD","LU0348723411.USD","LU1854104046.USD","LU0109394709.USD","LU0320765992.SGD","LU2360107325.USD","IE0002141913.USD","LU1548497426.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4141","BK4512","ONG","LU1861219969.SGD","RVMD","LU1861215975.USD","PTH","IE00BZ199S13.USD","LU2298322129.HKD","ON","LU2357305700.SGD","IE00BD6J9T35.USD","LU0124384867.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE0009354923.USD","IE00BJT1NW94.SGD","LU1978683503.SGD","BBH","LU1983260115.SGD","ONX","BK4139","CANC","BK4588","BK4585","LU1720051017.SGD","LU1854103824.USD","LU1861214812.USD","LU1861220033.SGD","IDNA","IE00BFMHRM44.USD","LU1720051108.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678919792","title":"Revolution Medicines Falls After Incyte Posts Competitive Pancreatic Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2678919792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678919792?lang=en_us&edition=fundamental","pubTime":"2026-10-27 00:04","pubTimestamp":1793030678,"startTime":"0","endTime":"0","summary":"BUZZ-Revolution Medicines falls after Incyte posts competitive pancreatic cancer data** Shares of Revolution MedicinesRVMD.Odown 1% at $185.06** IncyteINCY.Oreports an 89% response rate for its KRAS G","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nL3N46C1DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4139","IE00B2B36J28.USD","BK4550","LU0109394709.USD","LU0889565916.HKD","IE00BFTCPJ56.SGD","BK4532","BK4585","IE00BJT1NW94.SGD","IE0009355771.USD","BK4588","IE0009354923.USD","INCY","RVMD","CANC","IDNA","IE0002141913.USD","PTH","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677971003","title":"Moderna's Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.","url":"https://stock-news.laohu8.com/highlight/detail?id=2677971003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677971003?lang=en_us&edition=fundamental","pubTime":"2026-10-24 02:27","pubTimestamp":1792780020,"startTime":"0","endTime":"0","summary":"Moderna stock narrowly avoided its worst trading session on record after leaked data for its cancer-vaccine candidate triggered a wave of selling. But were investors right to panic?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRUH","LU0980610538.SGD","VHT","GDOC","PAWZ","LU0320765992.SGD","LGHT","RXL","JDOC","LU0070302665.USD","03165","LU0208291251.USD","SG9999001176.USD","IXJ","LU1941712348.USD","SG9999015341.SGD","LU0203345920.USD","IE00BLSP4452.SGD","PPH","FTXH","BK4568","LU0432979614.USD","BMED","SG9999014559.SGD","PTH","GNOM","CANC","BBH","BNTX","MRNA","LU0889565916.HKD","LU1066051225.USD","IHE","SG9999014575.USD","MRNX","RHHBY","LU1057294990.SGD","IDNA","LU0477156953.USD","LU1032466523.USD","RVMD","LU1989772840.SGD","WDNA","HRTS","LU1430594728.SGD","MRK","MRNY","FHLC","IYH","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677489929","title":"Revolution's Rasonque Improves Survival Across Subgroups in Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2677489929","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677489929?lang=en_us&edition=fundamental","pubTime":"2026-10-23 19:30","pubTimestamp":1792755000,"startTime":"0","endTime":"0","summary":"Revolution's Rasonque improves survival across subgroups in pancreatic cancer patientsOct 23 (Reuters)-Revolution MedicinesRVMD.Osaid on Friday itsrecently approved pancreatic cancer drug Rasonque imp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nL4N4690TC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","CANC","RVMD","IDNA","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00B2B36J28.USD","BK4139","BBH","IE0009355771.USD","IE00BJJMRZ35.SGD","IE0009354923.USD","IE0002141913.USD","IE00BJT1NW94.SGD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677917359","title":"BB Biotech Presents 23% Nine-Month NAV Gain in Swiss Francs","url":"https://stock-news.laohu8.com/highlight/detail?id=2677917359","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677917359?lang=en_us&edition=fundamental","pubTime":"2026-10-23 13:06","pubTimestamp":1792732015,"startTime":"0","endTime":"0","summary":"BB Biotech Presents 23% Nine-Month NAV Gain in Swiss FrancsBB Biotech’s net asset value rose 23% in CHF over the first nine months of 2026, trailing the NBI’s 31.8% gain.Its share price gained 21.5% i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nNDL7KqRtM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0545562505.USD","LU2236285917.USD","IBBQ","TBXU","IE0002141913.USD","BK4588","IE00B2B36J28.USD","LU0109394709.USD","BIB","IBB","LU2237438978.USD","GSK.UK","PTH","LU0320765992.SGD","SG9999001176.SGD","RVMD","CANC","SG9999001176.USD","LU0971552830.HKD","LU1064927863.SGD","GNMX","LU0987226296.USD","SG9999013999.USD","IE00BQJZX424.USD","BK4533","LU1015430645.USD","LU2362541273.HKD","IE00B894F039.SGD","VRTX","IE00BWDBJ516.SGD","IE00B19Z9Z06.USD","LU1670756490.USD","PBE","LU0432979614.USD","LU1046248800.SGD","LU1035777561.USD","LU0417517546.SGD","LU1645745479.HKD","LU1228905540.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","BK5011","BBH","LU0203347892.USD","LU0321505868.SGD","LU1309081286.SGD","LU0079474960.USD","IE00BZ9MQY76.HKD","LU2646069778.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677060405","title":"Revolution Medicines Sets Third-Quarter Results Release After Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2677060405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677060405?lang=en_us&edition=fundamental","pubTime":"2026-10-22 04:11","pubTimestamp":1792613488,"startTime":"0","endTime":"0","summary":"Revolution Medicines Sets Third-Quarter Results Release After Market CloseRevolution Medicines will report third-quarter 2026 financial results on November 4, 2026, following market close.Senior manag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL68b41g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","SG9999014013.SGD","IE0009354923.USD","SG9999014021.USD","IE0009355771.USD","LU0889565916.HKD","PTH","BBH","BK4588","IE00B2B36J28.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BQXX3F31.USD","IE00BJJMRZ35.SGD","LU2210150020.SGD","IDNA","IE00B64PRP62.GBP","LU0314104364.USD","BK4139","BK4585","BCDF","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BKPKM429.USD","LU2095319765.USD","BK4112","CANC","NDAQ","IE00BGHQF748.EUR","IE00BN0W2W23.USD","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677567451","title":"TD Cowen Remains a Buy on Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2677567451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677567451?lang=en_us&edition=fundamental","pubTime":"2026-10-21 20:59","pubTimestamp":1792587566,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines today and set a price target of $250.00. Van Buren covers the Heal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","BBH","RVMD","IE00BJJMRZ35.SGD","LU0109394709.USD","CANC","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","LU0320765992.SGD","BK4127","IE0009354923.USD","PTH","LU0889565916.HKD","IE00B2B36J28.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677131866","title":"Revolution Medicines Inc Stock (RVMD) Moved Up by 7.41% on Oct 20: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2677131866","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677131866?lang=en_us&edition=fundamental","pubTime":"2026-10-21 02:15","pubTimestamp":1792520121,"startTime":"0","endTime":"0","summary":"• Revolution Medicines initiated patient treatment in new global Phase 3 clinical trials.\n• Analysts published bullish notes and raised price targets for the company.\n• The company reported zero annual revenue and a net loss of $1.13B.","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262226488-market-movers-rvmd-20261020","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","IE0009355771.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4139","IE00BJJMRZ35.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE0002141913.USD","RVMD","IDNA","PTH","LU0109394709.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150070264","title":"Movement Alert｜Revolution Medicines, Inc. Intraday Rise 5.43% in Regular Trading, Phase 3 Lung Cancer Combination Trial Begins Dosing Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1150070264","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150070264?lang=en_us&edition=fundamental","pubTime":"2026-10-20 22:05","pubTimestamp":1792505114,"startTime":"0","endTime":"0","summary":"On October 20, Revolution Medicines, Inc. rose 5.43% in Regular Trading, trading at $191.36 per share, with turnover of $64.69 million.The move followed the company’s announcement that it has begun...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Revolution Medicines Rises as Phase 3 Lung Cancer Trial Begins","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676696338","title":"Revolution Medicines Starts Treating Patients in Phase 3 Trial for Zoldonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2676696338","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676696338?lang=en_us&edition=fundamental","pubTime":"2026-10-20 20:58","pubTimestamp":1792501109,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has started treating adult patients in its global phase 3 clinical trial evaluating its investigational drug zoldonrasib on non-squamous non-small cell lung cancer, the com","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBH","LU0320765992.SGD","IE00B2B36J28.USD","LU0109394709.USD","CANC","RVMD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4139","LU0889565916.HKD","IE0002141913.USD","PTH","IDNA","IE0009355771.USD","IE0009354923.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676693081","title":"Revolution Medicines begins treating patients in RASolve 308 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2676693081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676693081?lang=en_us&edition=fundamental","pubTime":"2026-10-20 20:20","pubTimestamp":1792498820,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-begins-treating-patients-in-rasolve-308-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-begins-treating-patients-in-rasolve-308-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","LU0109394709.USD","CANC","IE00BJT1NW94.SGD","PTH","MEDX","HYLG","IE00B4R5TH58.HKD","BBH","IE0002141913.USD","IDNA","NVIB","LU0320765992.SGD","IE0009354923.USD","LU0889565916.HKD","RVMD","GDOC","IE00BJJMRZ35.SGD","BK4139","IE00BFTCPJ56.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676698093","title":"Revolution Medicines Begins Treating Patients in Phase 3 Rasolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic Ras G12d Non-Squamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2676698093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676698093?lang=en_us&edition=fundamental","pubTime":"2026-10-20 20:00","pubTimestamp":1792497605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261020:nTUA7BF9QX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IDNA","IE0009354923.USD","BK4139","IE0009355771.USD","LU0889565916.HKD","CANC","IE0002141913.USD","PTH","IE00BJT1NW94.SGD","LU0109394709.USD","RVMD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676680134","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Evaxion Biotech (EVAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676680134","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676680134?lang=en_us&edition=fundamental","pubTime":"2026-10-20 00:50","pubTimestamp":1792428623,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Evaxion Biotech (EVA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-evaxion-biotech-evax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-evaxion-biotech-evax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","IDNA","IE00B4R5TH58.HKD","BK4581","XBI","IE00BJT1NW94.SGD","LU0128526141.USD","PTH","RVMD","IE00B2B36J28.USD","BBH","LU0029874061.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","XLV","IE0002141913.USD","LU0889565916.HKD","CANC","BK4139","BK4585","BK4137","BK4588","EVAX","IE0009354923.USD","HCSG","IE00BFTCPJ56.SGD","LU0320765992.SGD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676351901","title":"Moderna Stock Slumps, but It’s Too Early to Panic","url":"https://stock-news.laohu8.com/highlight/detail?id=2676351901","media":"Dow Jones","labels":["EditorSelect"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676351901?lang=en_us&edition=fundamental","pubTime":"2026-10-19 11:00","pubTimestamp":1792378800,"startTime":"0","endTime":"0","summary":"Biotechnology stocks slumped on Friday, led by declines in vaccine makers and drug developers.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"EditorSelect","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","MRNX","LU0109394709.USD","IE00B2B36J28.USD","GNOM","PTH","IE0009355771.USD","IE00BJT1NW94.SGD","MRNA","BK4501","IE0002141913.USD","BK4547","IE0009354923.USD","BK4534","WDNA","LGHT","BK4533","RVMD","BK4532","IE00BJJMRZ35.SGD","MRNY","BK4548","BK4585","BK4568","LU0889565916.HKD","BK4551","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4588","NVAX","BBH","BK4139","LU0320765992.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136921704","title":"Movement Alert｜Revolution Medicines, Inc. Falls 5.02% in Regular Trading, Recent Analyst Optimism Focused on Rasonque Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1136921704","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136921704?lang=en_us&edition=fundamental","pubTime":"2026-10-16 23:26","pubTimestamp":1792164362,"startTime":"0","endTime":"0","summary":"On October 16, Revolution Medicines, Inc. fell 5.02% in Regular Trading, trading at $179.4831 per share, with turnover of $111 million.The most recent company-specific catalyst in public reporting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"RBC Lifts Target to $259 as Revolution Medicines Drops","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0286},{"period":"1month","weight":-0.0645},{"period":"3month","weight":-0.018},{"period":"6month","weight":0.353},{"period":"1year","weight":2.2443},{"period":"ytd","weight":1.3694}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000417},{"month":8,"riseRate":0.714286,"avgChangeRate":0.065126},{"month":9,"riseRate":0.428571,"avgChangeRate":0.032485},{"month":10,"riseRate":0.571429,"avgChangeRate":0.005587},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}